Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi’s North America Pharma Head Whitaker Implements Patient Solution Responses to Commercial Challenges

Executive Summary

Since joining Sanofi as president of its North American Pharmaceuticals and Consumer Healthcare Businesses in mid-2011, Anne Whitaker has made important changes in the commercial organization to address the evolving market at a critical time for the company.

You may also be interested in...



Out With Experimentation, ZS Sees New Commercial Models Settling In

After several years of experimentation, big pharma has settled on new commercial models for their U.S. sales teams and are in various stages of implementation, according to ZS Associates Managing Director Chris Wright. The preferred models have commonalities built around a mix of traditional sales reps, key account managers and multi-channel digital tools.

Regeneron/Sanofi’s Long-Term Alliances Begin Bearing Fruit

Regeneron’s five-year-old antibody partnership with Sanofi may be expensive, but it is starting to produce some interesting compounds in mid-to-late-stage clinical trials, with positive data to show.

Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition

Responding to a convergence of a changing market and shifts in technology, pharmaceutical companies are exploring ways to enhance the value of their products and find new opportunities beyond their core molecule-driven businesses.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

PS054680

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel